Skip to content


Benlysta (belimumab) is an antibody pharmaceutical. Belimumab was first approved as Benlysta on 2011-03-09. It is used to treat systemic lupus erythematosus in the USA. It has been approved in Europe to treat systemic lupus erythematosus. The pharmaceutical is active against tumor necrosis factor ligand superfamily member 13B.
Trade Name Benlysta
Common Name Belimumab
Indication systemic lupus erythematosus
Drug Class Monoclonal antibodies
Get full access now